Electron spin resonance studies on caeruloplasmin and iron transferrin in patients with chronic lymphocytic leukaemia. by Green, J. A. et al.
Br. J. Cancer (1980) 41, 356
ELECTRON SPIN RESONANCE STUDIES ON CAERULOPLASMIN
AND IRON TRANSFERRIN IN PATIENTS WITH CHRONIC
LYMPHOCYTIC LEUKAEMIA
J. A. GREEN*, T. POCKLINGTONt, A. A. DAWSON* AND M. FOSTERt
From the Departments of *Medicine, Biomedical Physics and Bioengineering,
and tChemical Pathology, University of Aberdeen
Received 29 August 1979 Accepted 13 November 1979
Summary.-Whole-blood caeruloplasmin measured by electron spin resonance was
studied in 41 patients with chronic lymphocytic leukaemia. The levels were above
normal at all stages of the disease, rose with increasing clinical involvement, and
were higher in progressive than inactive disease. Whole-blood iron transferrin levels
were more variable, and were significantly raised only in patients with marrow
failure.
SERUM COPPER LEVELS have been
shown to correlate with disease activity
in Hodgkin's disease, non-Hodgkin's
lymphoma and acute leukaemia (Tessmer
et al., 1972; Hrgovcic et al., 1968; 1973a,b).
The enzyme caeruloplasmin contains 9500
of the total blood copper, and may be
associated with iron metabolism and
storage (Frieden, 1973). Previous studies
by our group have demonstrated a rise in
blood caeruloplasmin and a fall in blood
iron transferrin levels in Hodgkin's
disease. Serial measurement of these
parameters was found to assist early pre-
diction of reactivation of disease and in
monitoring response to treatment (Foster
et al., 1977a). Other workers have noted a
fall in serum iron levels in Hodgkin's
disease, but have disagreed about their
clinical value (Jaffe & Bishop, 1970;
Beamish et al., 1972; Ray et al., 1973).
In the non-Hodgkin's lymphomas, ab-
normal iron, copper and caeruloplasmin
levels have been found, but their clinical
usefulness has yet to be proved (Foster et
al., 1977b). Hypercupraemia has also been
found in conditions other than the
lymphoreticular disorders, e.g. in preg-
nancy (Lahey et al., 1953), infection
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(Markovitz et al., 1955) and in other
malignancies (Fisher & Shifrine, 1978;
Andrews, 1979). The significance of raised
copper levels in malignancy has been
debated (Pocklington & Foster, 1977).
In chronic lymphocytic leukaemia
(CLL) a disease which can be regarded as
a form of non-Hodgkin's lymphoma of
B-cell origin, prediction of subsequent
biological behaviour is a major clinical
problem. The aim of this study was to
compare whole-blood caeruloplasnmin and
iron transferrin levels with the classical
guides to activity of this disease: white-
cell count, platelet count, lymphadeno-
pathy, hepatomegaly and splenomegaly.
As these parameters do not always
adequately assess disease activity, an
arbitrary clinical assessment of the direc-
tion and rate of change of these clinical
and laboratory findings was also used for
comparison.
PATIENTS AND METHODS
Forty-one outpatients with unequivocal
CLL (peripheral-blood lymphocytosis of more
than 10 x 109/1 in the absence of infection
and, in doubtful cases, lymphocytosis in
marrow aspirate) were studied. Twenty were
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TABLE I.-The variation in whole-blood caeruloplasmin, transferrin (ESR units) and
white-cell count and packed-cell volume with clinico-pathological stage in chroniclympho-
cytic leukaemtia (CLL). The Rai (1975) equivalent stages are approximate
Normal
CLL Subelinical
CLL Nodes only
CLL Spleen only
CLL Spleen+nodes
CLL Liver, spleen+nodes
CLL Platelets <100 x 109/1
Rai
stage
0
I
II
II
II
IV
n
180
53
73
63
48
40
35
Mean
caerulo-
plasmin s.e.
1*170
1*519
1-708
1-769
1-805
1-814
1-610
0-02
0 054
0-065
0-068
0-083
0-088
0*093
Mean
* trans-
P ferrin s.e.
0 0005
0*0005
0 0005
0*0005
0 0005
0-0025
1-095
1-180
1-261
1-296
1-280
1*338
1-638
0-036
0-073
0-085
0-091
0-108
0-127
0-134
Mean
* WBC PCV
P (109/1) (%) s.e.
NS 31 38-6 0-086
NS 97 36.6 0-640
NS 110 36-0 0.815
NS 131 35-8 0*888
NS 152 35*1 0-992
0005 120 34-8 1-164
Notes
n=Number ofmeasurements in each subgroup.
* Significance of difference between CLL subgroup and normal population.
PCV=Packed cell volume.
male, 21 female, and the mean age at the
start ofthe observation period (3-14 months)
was 68-3 (range 52-88). At each visit the
haemoglobin, packed-cell volume, white-cell
count, platelet count and the sizes ofthe liver,
spleen and nodes were recorded. When the
data were subsequently analysed, a staging
system broadly similar to the Rai et al. (1975)
classification was used. This attempts to
assess total lymphocyte mass from the
peripheral-blood picture and the presence or
absence of clinical disease. No equivalent of
the Rai Stage III (haemoglobin less than
10 g/dl) was used in view of transfusion
artefact. A further assessment of disease
activity, based on the progression in physical
signs, constitutional symptoms and haemato-
logical indices was made. Group I comprised
patients with inactive disease, Group II
intermediate activity and Group III pro-
gressive disease. Thirty-four patients re-
ceived cytotoxic therapy during all or part of
the study. One patient taking an oestrogen
contraceptive was excluded from the analysis.
Caeruloplasmin and iron transferrin levels
were measured by the technique of electron
spin resonance on whole blood frozen in
spectrum-free tubes in liquid N2 (Foster et al.,
1973) at each clinic visit. A total of 129
samples were examined for each protein, and
the results expressed as apeak-to-peak height,
the normal whole-blood levels being 1-17 +
(s.d.) 0-268 for caeruloplasmin and 1-095 +
0 377 for iron transferrin. Statistical com-
parisons were made using Student's t test of
the differences between the means.
RESULTS
Table I shows the rise in whole-blood
caeruloplasmin with increasing lympho-
cyte mass. At all stages ofthe disease, the
caeruloplasmin level was significantly
greater than normal (P> 0.0025), and in
the "spleen palpable", "spleen plus nodes
palpable", and "spleen liver and nodes
palpable" groups the caeruloplasmin was
also significantly higher (P< 0 005) than
in the subclinical group (Rai Stage 0).
Blood transferrin levels showed the same
trend but the range of values was much
greater, and the levels were significantly
(P < 0.005) above normal only in the
marrow-failure group (platelets <100 x
109/1). The last column shows the expected
rise in white-cell count with clinical en-
largement of the lymph nodes, spleen and
liver. The mean packed-cell volume fell
progressively from 38.6% in the sub-
clinical group to 34.8% in the advanced-
disease group. Plasma caeruloplasmin and
iron transferrin were measured con-
currently, mean plasma caeruloplasmin
showed a similar but less marked rise with
disease progression and mean plasma iron
transferrin was significantly raised only in
the marrow-failure group. There was no
significant correlation between packed-
cell volume and the whole-blood or plasma
levels of either protein.
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TABLE II.-The variation in whole-blood
caeruloplasmin and transferrin (ESR
units) with clinico-pathological pro-
gression ofchronic lymphocytic leukaemia
(CLL). The caeruloplasmin levels in
Group III were significantly higher than
those in Groups I and II (P< 0 025).
Mean Mean
caerulo- trans-
n plasmin s.e. ferrin s.e.
CLL activity
Normal 180 1-170 0-02 1P095 0-036
Group I 58 1-544 0-064 1-051 0-067
Group II 22 1-540 0077 1-619 0*190
Group III 48 1-771 0 077 1-217 0*088
When the data were analysed by the
arbitrary clinical assessment of activity
(Table II) a rise in caeruloplasmin with
activity was seen, whereas iron transferrin
was raised only in the group with inter-
mediate activity. There was no correlation
between either metalloprotein and the
total white-cell count, platelet count,
haemoglobin or packed-cell volume. There
was no sex difference in CLL patients,
although a slight difference has been
shown between normal males and females
(Pocklington & Foster, 1977).
DISCUSSION
The variation found in the iron trans-
ferrin levels was too great for this assess-
ment to be of clinical value. Blood trans-
fusion may account for some of this
variation, and may explain the low values
in the marrow-failure group. No explana-
tion can be given for the raised levels in
the intermediate-activity group (Table II).
The fall in iron transferrin noted in active
Hodgkin's disease was not seen in CLL,
whereas in the more closely related non-
Hodgkin's lymphoma cases there was no
significant abnormality in their iron trans-
ferrin levels (Foster et al., 1977b).
The data show that whole blood
caeruloplasmin levels in CLL reflect the
extent of the disease, as judged by the
accepted prognostic criteria: white-cell
count, platelet count, and organomegaly.
Even in the absence ofall clinical evidence
ofdisease, the whole-blood caeruloplasmin
was raised. When the more dynamic but
less reproducible criteria ofdisease activity
was used, the whole-blood caeruloplasmin
increased with progressive disease. It may
be that the rate of cell turnover rather
than absolute lymphocyte mass deter-
mines the likelihood of progression in
CLL. In acute leukaemia, serum copper
has been shown to reflect accurately
marrow cell turnover (Tessmer et al., 1972)
and to rise pari passu the blast-cell count.
The precise reason for this rise has not
been proved, but increased glycoprotein
metabolism in cell-membrane synthesis
and degradation may be responsible
(Fisher & Shifrine, 1978).
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